Abstract
Drug-drug interactions (DDIs) are a major cause of adverse drug effects and a public health concern, as they increase hospital care expenses and reduce patients' quality of life. DDI detection is, therefore, an important objective in patient safety, one whose pursuit affects drug development and pharmacovigilance. In this article, we describe a protocol applicable on a large scale to predict novel DDIs based on similarity of drug interaction candidates to drugs involved in established DDIs. The method integrates a reference standard database of known DDIs with drug similarity information extracted from different sources, such as 2D and 3D molecular structure, interaction profile, target and side-effect similarities. The method is interpretable in that it generates drug interaction candidates that are traceable to pharmacological or clinical effects. We describe a protocol with applications in patient safety and preclinical toxicity screening. The time frame to implement this protocol is 5–7 h, with additional time potentially necessary, depending on the complexity of the reference standard DDI database and the similarity measures implemented.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pirmohamed, M. & Orme, M.L. Drug Interactions of Clinical Importance. Chapman & Hall 1998.
Tatonetti, N.P., Fernald, G.H. & Altman, R.B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J. Am. Med. Inform. Assoc. 19, 79–85 (2012).
US Food and Drug Administration (FDA) http://www.fda.gov/ (accessed April 2013).
Becker, M.L. et al. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol. Drug Saf. 16, 641–651 (2007).
Bjornsson, T.D. et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815–832 (2003).
Vilar, S. et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J. Am. Med. Inform. Assoc. 18, I73–I80 (2011).
Vilar, S., Harpaz, R., Santana, L., Uriarte, E. & Friedman, C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS ONE 7, e41471 (2012).
Vilar, S. et al. Drug-drug interaction through molecular structure similarity analysis. J. Am. Med. Inform. Assoc. 19, 1066–1074 (2012).
Vilar, S., Uriarte, E., Santana, L., Tatonetti, N.P. & Friedman, C. Detection of drug-drug interactions by modeling interaction profile fingerprints. PLoS ONE 8, e58321 (2013).
Vilar, S., Uriarte, E., Santana, L., Friedman, C. & Tatonetti, N.P. State of the art and development of a new drug-drug interaction large-scale predictor based on 3D pharmacophoric similarity. Curr. Drug Metabolism. 15, in press (2014).
Durant, J.L., Leland, B.A., Henry, D.R. & Nourse, J.G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 42, 1273–1280 (2002).
Liu, M. et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J. Am. Med. Inform. Assoc. 19(e1), e28–e35 (2012).
Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263–266 (2008).
Dixon, S.L. et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20, 647–671 (2006).
Fowler, S. & Zhang, H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J. 10, 410–424 (2008).
Hudelson, M.G. et al. High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods. J. Med. Chem. 51, 648–654 (2008).
Pang, K.S., Rodrigues, A.D. & Peter, R.M. (eds.), Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. Springer, 2010.
Jonker, D.M., Visser, S.A.G., van der Graaf, P.H., Voskuyl, R.A. & Danhof, M. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther. 106, 1–18 (2005).
Rahnasto, M., Raunio, H., Poso, A., Wittekindt, C. & Juvonen, R.O. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem. 48, 440–449 (2005).
Afzelius, L. et al. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol. Pharmacol. 59, 909–919 (2001).
De Rienzo, F., Fanelli, F., Menziani, M.C. & De Benedetti, P.G. Theoretical investigation of substrate specificity for cytochromes p450 IA2, p450 IID6 and p450 IIIA4. J. Comput. Aided Mol. Des. 14, 93–116 (2000).
Percha, B., Garten, Y. & Altman, R.B. Discovery and explanation of drug-drug interactions via text mining. Pac. Symp. Biocomput. 2012, 410–421 (2012).
Tari, L., Anwar, S., Liang, S., Cai, J. & Baral, C. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics 26, i547–i553 (2010).
Percha, B. & Altman, R.B. Informatics confronts drug-drug interactions. Trends Pharmacol. Sci. 34, 178–184 (2013).
Gottlieb, A., Stein, G.Y., Oron, Y., Ruppin, E. & Sharan, R. INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol. Syst. Biol. 8, 592 (2012).
Hill, T. & Lewicki, P. Statistics Methods and Applications. A Comprehensive Reference for Science, Industry and Data Mining. StatSoft, 2006.
Tatonetti, N.P., Ye, P.P., Daneshjou, R. & Altman, R.B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 4, 125ra31 (2012).
Olvey, E.L., Clauschee, S. & Malone, D.C. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin. Pharmacol. Ther. 87, 48–51 (2010).
Acknowledgements
This study was supported by 'Plan Galego de Investigación, Innovación e Crecemento 2011-2015 (I2C)', by the European Social Fund (ESF), by the Angeles Alvariño program from Xunta de Galicia (Spain) (S.V.), by a training grant from the National Heart, Lung, and Blood Institute (NHLBI) T32HL120826 (T.L.), and by a Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Research Starter Award (N.P.T.), as well as by grants R01 LM010016, R01 LM010016-0S1, R01 LM010016-0S2 and R01 LM008635 (C.F.).
Author information
Authors and Affiliations
Contributions
S.V., C.F. and N.P.T. conceived and designed the experiments; S.V. performed the experiments; S.V. and N.P.T. analyzed the data; S.V., E.U., L.S., T.L., G.H., C.F. and N.P.T. contributed reagents/materials/analysis tools; and S.V., E.U. and N.P.T. wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Vilar, S., Uriarte, E., Santana, L. et al. Similarity-based modeling in large-scale prediction of drug-drug interactions. Nat Protoc 9, 2147–2163 (2014). https://doi.org/10.1038/nprot.2014.151
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2014.151
This article is cited by
-
MCL-DTI: using drug multimodal information and bi-directional cross-attention learning method for predicting drug–target interaction
BMC Bioinformatics (2023)
-
Analysis and identification of drug similarity through drug side effects and indications data
BMC Medical Informatics and Decision Making (2023)
-
Multi-view feature representation and fusion for drug-drug interactions prediction
BMC Bioinformatics (2023)
-
Multitask joint strategies of self-supervised representation learning on biomedical networks for drug discovery
Nature Machine Intelligence (2023)
-
MDDI-SCL: predicting multi-type drug-drug interactions via supervised contrastive learning
Journal of Cheminformatics (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.